<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="180196">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748956</url>
  </required_header>
  <id_info>
    <org_study_id>GCO-05-0986</org_study_id>
    <secondary_id>PT050986</secondary_id>
    <nct_id>NCT00748956</nct_id>
  </id_info>
  <brief_title>Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers</brief_title>
  <acronym>NPY</acronym>
  <official_title>Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dennis Charney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is growing evidence that neuropeptides act as neuronal messengers in the brain and
      have diverse functions that may include the regulation of mood and behavior. For example,
      neuropeptide Y (NPY) is thought to play a role in the adaptive stress response. The
      therapeutic application of neuropeptides for psychiatric disorders has been limited by
      difficult and unreliable penetration of the blood-brain barrier (BBB). However, recent data
      suggest that intranasal administration may provide a means of effectively delivering some of
      these neuropeptides to the brain. Thus far it is unclear if this is the case for NPY. The
      aims of this project are:

        1. To evaluate, in 15 healthy male volunteers aged 25-45, the effect of intranasal NPY
           administration (0, 50 and 100 nmol) on its levels in cerebrospinal fluid (CSF),
           measured by means of lumbar puncture using an intraspinal catheter between L4 and L5,
           and in plasma, measured using an intravenous catheter in the forearm. One of the three
           treatments will be administered to each participant in a double-blind fashion. The 0
           nmol condition will serve as the placebo control.

        2. To test the effect of intranasal NPY administration on mood and anxiety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is growing evidence that neuropeptides, including neuropeptide Y (NPY), act as
      neuronal messengers in the brain and have diverse neurobehavioral functions. Their
      therapeutic application for psychiatric disorders has been limited, however, by difficult
      and unreliable penetration of the blood-brain barrier (BBB). The BBB has prevented the use
      of many therapeutic agents for treating central nervous system (CNS) disorders. Several
      molecules have successfully been administered through intranasal delivery, however, thanks
      to the unique connection that the nerves involved in sensing odors and chemicals provide
      between the CNS and its environment.

      NPY, the most abundant peptide in the mammalian brain, is co-localized with norepinephrine
      in sympathetic nerve fibers and has been of longstanding interest to our research group
      (Morgan et al., 2002; Morgan et al., 2003; Morgan et al., 2001; Morgan et al., 2000;
      Rasmusson et al., 2000; Rasmusson et al., 1998) because of its potential role in modulating
      mood and anxiety. NPY has been implicated as factor in the adaptive stress response
      (Thorsell et al., 1999), and has been shown to impact the consolidation of fear-related
      memories after shock (Flood et al., 1989). Clinically, lower plasma NPY levels have been
      correlated with greater psychological distress, increased symptoms of dissociation, and
      poorer performance among active duty military personnel. Acute stress in humans has been
      found to elicit NPY release, in a manner parallel to the changes in cortisol and
      norepinephrine that are usually seen, with a blunting of the plasma NPY response in response
      to yohimbine (Morgan et al., 2002). Baseline NPY levels in combat veterans with PTSD are
      reduced compared to healthy non-traumatized individuals (Rasmusson et al., 2000). Another
      study found that repeated exposure to traumatic stress, rather than the presence of PTSD or
      PTSD-type symptoms, is associated with a reduction in baseline plasma NPY (Morgan et al.,
      2003). A recent report found deceased CSF concentrations of NPY in patients with treatment
      resistant unipolar major depression (Heilig et al 2004). In summary, there has been
      suggestion from studies in patients with anxiety and mood disorders as well as healthy
      volunteers of an abnormal regulation of this peptide.

      In this study, we will evaluate intranasal administration of NPY in healthy male volunteers
      ages 25-45 using a specialized delivery device. Pending the initial feasibility and
      tolerability in healthy volunteers, future protocols will examine the effect of intranasal
      NPY administration in patients with disorders such as PTSD, major depression, panic
      disorder, and social anxiety disorder.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of NPY in CSF and plasma</measure>
    <time_frame>on study day 2</time_frame>
    <description>samples collected at 10 min and 20 minute intervals in 2 hours post intranasal administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systematic Assessment of Treatment-Emergent Effects (SAFTEE)</measure>
    <time_frame>on study day 2</time_frame>
    <description>measure in 2 hours post intranasal administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite Scale</measure>
    <time_frame>on study day 2</time_frame>
    <description>measure in 2 hours post intranasal administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-sleep questionnaire</measure>
    <time_frame>on study day 2</time_frame>
    <description>measure in the morning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms (QIDS)</measure>
    <time_frame>on study day 2</time_frame>
    <description>measure in 2 hours post intranasal administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Mood States (POMS)</measure>
    <time_frame>on study day 2</time_frame>
    <description>measure in 2 hours post intranasal administration and on the next morning</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Mood Disorder</condition>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Low dose NPY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose, Receive 50 nmol dose of NPY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose NPY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose, Receive 100 nmol dose of NPY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose NPY</intervention_name>
    <description>50nmol, administered intranasally</description>
    <arm_group_label>Low dose NPY</arm_group_label>
    <other_name>Neuropeptide Y</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose NPY</intervention_name>
    <description>100nmol administered intranasally</description>
    <arm_group_label>High dose NPY</arm_group_label>
    <other_name>Neuropeptide Y</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo comparator (0nmol)) administered intranasally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 25-45.

          -  No history of Axis I disorder as defined in the DSM-IV other than past nicotine abuse
             or dependence or adjustment disorder.

        Exclusion Criteria:

          -  Nicotine or caffeine abuse or dependence within the preceding 3 months.

          -  History or complaint of nasal disorders or allergies.

          -  Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory,
             cardiovascular, endocrinologic, neurologic, immunologic, or hematologic.

          -  Significant obesity (BMI &gt; 30), scoliosis, spinal stenosis or a history of
             lumbosacral laminectomy.

          -  Clinically significant abnormal findings of laboratory parameters, physical
             examination, or ECG.

          -  Current use of any medications that have effects on CNS function.

          -  Prior sinonasal surgery, or significant nasal polyps as determined by nasal
             endoscopy.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Feder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis Charney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Morgan CA 3rd, Rasmusson AM, Winters B, Hauger RL, Morgan J, Hazlett G, Southwick S. Trauma exposure rather than posttraumatic stress disorder is associated with reduced baseline plasma neuropeptide-Y levels. Biol Psychiatry. 2003 Nov 15;54(10):1087-91.</citation>
    <PMID>14625151</PMID>
  </reference>
  <reference>
    <citation>Morgan CA 3rd, Wang S, Southwick SM, Rasmusson A, Hazlett G, Hauger RL, Charney DS. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol Psychiatry. 2000 May 15;47(10):902-9.</citation>
    <PMID>10807963</PMID>
  </reference>
  <reference>
    <citation>Rasmusson AM, Hauger RL, Morgan CA, Bremner JD, Charney DS, Southwick SM. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol Psychiatry. 2000 Mar 15;47(6):526-39.</citation>
    <PMID>10715359</PMID>
  </reference>
  <reference>
    <citation>Rasmusson AM, Southwick SM, Hauger RL, Charney DS. Plasma neuropeptide Y (NPY) increases in humans in response to the alpha 2 antagonist yohimbine. Neuropsychopharmacology. 1998 Jul;19(1):95-8.</citation>
    <PMID>9608581</PMID>
  </reference>
  <reference>
    <citation>Thorsell A, Carlsson K, Ekman R, Heilig M. Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport. 1999 Sep 29;10(14):3003-7.</citation>
    <PMID>10549813</PMID>
  </reference>
  <reference>
    <citation>Flood JF, Baker ML, Hernandez EN, Morley JE. Modulation of memory processing by neuropeptide Y varies with brain injection site. Brain Res. 1989 Nov 27;503(1):73-82.</citation>
    <PMID>2611661</PMID>
  </reference>
  <reference>
    <citation>Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides. 2004 Aug;38(4):213-24. Review.</citation>
    <PMID>15337373</PMID>
  </reference>
  <reference>
    <citation>Eaton K, Sallee FR, Sah R. Relevance of neuropeptide Y (NPY) in psychiatry. Curr Top Med Chem. 2007;7(17):1645-59. Review.</citation>
    <PMID>17979774</PMID>
  </reference>
  <reference>
    <citation>Nikisch G, Agren H, Eap CB, Czernik A, Baumann P, Math√© AA. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol. 2005 Sep;8(3):403-10. Epub 2005 Mar 23.</citation>
    <PMID>15784158</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 10, 2012</lastchanged_date>
  <firstreceived_date>September 8, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mount Sinai School of Medicine</investigator_affiliation>
    <investigator_full_name>Dennis Charney</investigator_full_name>
    <investigator_title>Dean</investigator_title>
  </responsible_party>
  <keyword>Mood Disorder</keyword>
  <keyword>Anxiety Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
